| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1087057113487208 |
| P698 | PubMed publication ID | 23686103 |
| P2093 | author name string | Bryan P Kwan | |
| Mark L Cunningham | |||
| Karen J Shaw | |||
| Daniel C Bensen | |||
| Kirk J Nelson | |||
| P2860 | cites work | Mechanistic studies and biological activity of bioxalomycin alpha 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508. | Q33756862 |
| Mode of action of fluoroquinolones | Q33770059 | ||
| Mechanisms of action and resistance of older and newer fluoroquinolones | Q34030757 | ||
| Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. | Q34214929 | ||
| Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples | Q35816625 | ||
| Antibiotics: where did we go wrong? | Q36022317 | ||
| DNA gyrase on the bacterial chromosome: possibility of two levels of action | Q36416888 | ||
| Interaction of rifamycin with bacterial RNA polymerase | Q36475805 | ||
| Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus | Q38898667 | ||
| Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032) | Q39816283 | ||
| Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound | Q39832267 | ||
| Nalidixic Acid: an Antibacterial Paradox | Q40944835 | ||
| Specific stimulation of ribosomal RNA synthesis in E. coli by a protein factor | Q42466637 | ||
| Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus | Q44049965 | ||
| Antimicrobials: new solutions badly needed | Q44962251 | ||
| Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity. | Q45207323 | ||
| Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus | Q46453501 | ||
| The mechanism of inhibition of topoisomerase IV by quinolone antibacterials | Q46829877 | ||
| P433 | issue | 9 | |
| P921 | main subject | drug discovery | Q1418791 |
| macromolecule | Q178593 | ||
| P304 | page(s) | 1018-1026 | |
| P577 | publication date | 2013-05-17 | |
| P1433 | published in | Journal of Biomolecular Screening | Q6294856 |
| P1476 | title | Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay. | |
| P478 | volume | 18 |
| Q36489323 | A Peptidomimetic Antibiotic Targets Outer Membrane Proteins and Disrupts Selectively the Outer Membrane in Escherichia coli |
| Q47836437 | A quinolinol-based small molecule with anti-MRSA activity that targets bacterial membrane and promotes fermentative metabolism |
| Q47804224 | Actinorhodin is a redox-active antibiotic with a complex mode of action against Gram-positive cells. |
| Q34617861 | Amicoumacin a inhibits translation by stabilizing mRNA interaction with the ribosome |
| Q34098134 | Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus |
| Q37158570 | Chrysophaentins are competitive inhibitors of FtsZ and inhibit Z-ring formation in live bacteria |
| Q40077119 | Development of methionyl-tRNA synthetase inhibitors as antibiotics for Gram-positive bacterial infections. |
| Q38367630 | Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics |
| Q91882949 | Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase |
| Q38710256 | Strategies for target identification of antimicrobial natural products |
| Q89916856 | Structural approaches to pathway-specific antimicrobial agents |
| Q88914268 | Synthesis and Biological Evaluation of the Antimicrobial Natural Product Lipoxazolidinone A |
| Q59132640 | Thanatin targets the intermembrane protein complex required for lipopolysaccharide transport in |
| Q28538023 | Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents |
| Q36730046 | Untargeted Metabolomics To Ascertain Antibiotic Modes of Action. |
Search more.